The development of vaccines against polysaccharide-encapsulated pathogens (eg
Haemophilus influenzae type b, pneumococci, meningococci) is challenging because …

Since the introduction of monovalent meningococcal serogroup C (MenC) glycoconjugate
(MCC) vaccines and the implementation of national vaccination programmes, the incidence …

Background Since 2009, the incidence of meningococcal serogroup W disease has
increased rapidly in the UK because of a single strain (the so-called original UK strain) …

Background This paper outlines the methodology, study population and response rate of a
third large Dutch population-based cross-sectional serosurvey carried-out in 2016/2017 …

The annual incidence rate of serogroup W invasive meningococcal disease in the
Netherlands increased from< 0.05/100,000 (n< 10) before 2015 to 0.5/100,000 (n= 80) in …

Background. Vaccination with meningococcal serogroup C (MenC) conjugate (MCC)
polysaccharide vaccines led to a substantial decline in MenC disease in the vaccinated and …

Background. Several countries consider the implementation of a meningococcal serogroup
B vaccine for young children and/or serogroup C or ACWY conjugate vaccine for …

Vaccines have revolutionized public health, preventing millions of deaths each year,
particularly in childhood. Yet, there is considerable variability in the magnitude and …

Objective: Recently, a vaccine with the capacity to protect against serogroup B
meningococcal (MenB) disease received a positive opinion of the European Medicines …

Serogroup C meningococcal disease incidence and carriage declined rapidly in the United
Kingdom after infant serogroup C conjugate vaccination was introduced in 1999, with catch …